Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
POAI 
Predictive Oncology Inc (POAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: POAI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit -9.99% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.67M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 5501073 | Beta 1.22 | 52 Weeks Range 0.55 - 2.59 | Updated Date 04/1/2025 |
52 Weeks Range 0.55 - 2.59 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.96 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-26 | When Before Market | Estimate -0.25 | Actual -0.24 |
Profitability
Profit Margin - | Operating Margin (TTM) -669.39% |
Management Effectiveness
Return on Assets (TTM) -66.44% | Return on Equity (TTM) -201.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10349696 | Price to Sales(TTM) 7.19 |
Enterprise Value 10349696 | Price to Sales(TTM) 7.19 | ||
Enterprise Value to Revenue 6.97 | Enterprise Value to EBITDA -0.51 | Shares Outstanding 7209700 | Shares Floating 6560854 |
Shares Outstanding 7209700 | Shares Floating 6560854 | ||
Percent Insiders 1.47 | Percent Institutions 3.34 |
Analyst Ratings
Rating 3 | Target Price 3 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Predictive Oncology Inc
Company Overview
History and Background
Predictive Oncology Inc. (POAI), founded in 2000 (as Paradigm Medical Industries), initially focused on medical devices before transitioning to oncology research and diagnostics. The company has undergone several strategic shifts, including acquisitions and divestitures, to focus on personalized cancer treatment prediction.
Core Business Areas
- Drug Development Services: Offers services like cell-based assays, drug screening, and biomarker identification to pharmaceutical and biotechnology companies to aid in their drug development pipelines.
- AI-Powered Platforms: Develops and commercializes AI-driven platforms like PeDAL and TumorGenesis, which aim to predict patient responses to cancer therapies and aid in personalized medicine approaches.
Leadership and Structure
Raymond F. Vennare serves as the Chief Executive Officer. The organizational structure includes departments focused on research and development, sales and marketing, and finance and operations. A Board of Directors provides governance and strategic oversight.
Top Products and Market Share
Key Offerings
- PeDAL (Personalized Drug Assistance Learning): An AI-powered platform that analyzes patient-specific data to predict drug response and identify optimal treatment strategies. Market share data is not publicly available. Competitors include companies offering similar AI-driven solutions for drug discovery and personalized medicine, such as Recursion Pharmaceuticals (RXRX) and Schrodinger (SDGR).
- TumorGenesis: A 3D tumor microenvironment platform that mimics in vivo conditions to evaluate drug efficacy and predict patient response. Market share data is not publicly available. Competitors include companies offering 3D cell culture and microenvironment solutions, such as Corning Incorporated (GLW) and Thermo Fisher Scientific (TMO).
Market Dynamics
Industry Overview
The oncology drug development market is characterized by high unmet needs, increasing R&D spending, and a growing focus on personalized medicine. The market is highly competitive, with numerous companies developing novel therapies and diagnostic tools.
Positioning
Predictive Oncology positions itself as a provider of AI-powered solutions for personalized cancer treatment. Its competitive advantages include its proprietary AI platform and 3D tumor microenvironment technology. However, it faces competition from larger, more established companies with greater resources.
Total Addressable Market (TAM)
The TAM for personalized cancer treatment prediction is estimated to be billions of dollars and growing, driven by the increasing adoption of precision medicine approaches. Predictive Oncology is positioned to capture a portion of this market by offering AI-driven solutions for drug development and treatment selection.
Upturn SWOT Analysis
Strengths
- Proprietary AI-powered platform (PeDAL)
- 3D tumor microenvironment technology (TumorGenesis)
- Focus on personalized cancer treatment
- Experienced management team
Weaknesses
- Limited financial resources
- Small market share compared to competitors
- Dependence on strategic partnerships
- History of losses
Opportunities
- Growing demand for personalized medicine
- Increasing R&D spending in oncology
- Potential for strategic alliances and partnerships
- Expansion into new markets
Threats
- Competition from larger, more established companies
- Regulatory hurdles
- Technological advancements by competitors
- Economic downturn
Competitors and Market Share
Key Competitors
- RXRX
- TMO
- GLW
- SDGR
Competitive Landscape
Predictive Oncology faces significant competition from larger, more established companies with greater resources and brand recognition. Its competitive advantage lies in its AI-powered platform and 3D tumor microenvironment technology, but it needs to scale its operations and secure additional funding to compete effectively.
Major Acquisitions
Skyline Medical Inc.
- Year: 2020
- Acquisition Price (USD millions): 0
- Strategic Rationale: Reverse merger which provided Predictive Oncology access to public markets.
Growth Trajectory and Initiatives
Historical Growth: Growth has been inconsistent, with periods of rapid revenue increase followed by periods of decline. Historically, the company's revenue and profitability have been volatile.
Future Projections: Future projections are difficult to determine without analyst estimates. Growth will depend on the successful commercialization of PeDAL and TumorGenesis.
Recent Initiatives: Recent initiatives include the launch of new AI-powered solutions, strategic partnerships with pharmaceutical companies, and efforts to expand into new markets.
Summary
Predictive Oncology is a small company with innovative AI and 3D tumor technology aimed at personalized cancer treatment. They face intense competition from larger, more established players. Their strengths lie in their proprietary platforms, but weaknesses include limited resources and historical losses. Future success depends on securing funding, successful commercialization, and strategic partnerships.
Similar Companies
GLW
Corning Incorporated
GLW
Corning Incorporated
RXRX
Recursion Pharmaceuticals Inc
RXRX
Recursion Pharmaceuticals Inc
SDGR
Schrodinger Inc
SDGR
Schrodinger Inc
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (limited due to access)
- Industry Reports
- News Articles
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Financial data is based on publicly available information and may be outdated. Investment decisions should be made based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Predictive Oncology Inc
Exchange NASDAQ | Headquaters Pittsburgh, PA, United States | ||
IPO Launch date 2018-01-29 | CEO & Chairman Mr. Raymond F. Vennare | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 34 | |
Full time employees 34 | |||
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies. It operates through three segments: Pittsburgh, Birmingham, and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of approximately 150,000 tumor samples and creates proprietary 3D culture models used in drug development. The Birmingham segment offers contract services and research focused on solubility improvements, stability studies, and protein production. The Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Pittsburgh, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.